First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Objective The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.Methods and analysis In this non-randomised, open-label, three-part phase 1 study, INCB001158 wa...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Smith, Aung Naing, Todd Bauer, Kyriakos P Papadopoulos, Osama Rahma, Elena Garralda, Glenn J Hanna, Michael J Pishvaian, Xuejun Chen, Sven Gogov, Omar Saavedra, Howard Kallender, LuLu Cheng, Emil Kuriakose
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:BMJ Oncology
Online Access:https://bmjoncology.bmj.com/content/3/1/e000249.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjoncology.bmj.com/content/3/1/e000249.full

Similar Items